Pharvaris NV美股招股说明书(2025-07-22版)

PRELIMINARY PROSPECTUS SUPPLEMENT(to Prospectus dated April12, 2024) $150,000,000 ordinary shares Our ordinary shares are listed on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “PHVS.” On July21,2025, the last sale price of our ordinary shares as reported on Nasdaq was $23.84 per ordinary share. $Underwriting discounts and commissions(1)$Proceeds, before expenses, to us$ (1)We refer you to “Underwriting” beginning onpageS-21for additional information regarding underwriting compensation.We have granted the underwriters an option for a period of 30 days to purchase up to an additional$22,500,000 of ordinaryshares from us, at the public offering price, less the underwriting discounts and commissions. The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. Aregistration statement has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectussupplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy thesesecurities in any state where the offer or sale is not permitted.The ordinary shares will be ready for delivery on or about, 2025.Joint Book-Running ManagersMorganStanleyLeerinkPartnersCantorOppenheimer&Co.VanLanschotKempen supersedes the earlier statement.We have not authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus supplementand any related free writing prospectus filed by us with the SEC. We have not, and the underwriters have not, authorized anyone to provide you with this prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitationis unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference and any relatedfree writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may havechanged materially since those dates. This prospectus supplement and the financial statements and other documents incorporated by reference in this prospectus supplement and theaccompanying prospectus contain forward-looking statements, including statements concerning our use of proceeds, industry, our operations, ouranticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts. Thesestatements constitute forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, or the Securities Act,and Section21E of the Exchange Act. Many of the forward-looking statements contained in this prospectus supplement can be identified by the use offorward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others. Readers The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or thoseanticipated or predicted by our forward-looking statements:•uncertainty in the outcome of our interactions with regulatory authorities, including the U.S. Food and Drug Administration or FDA, with respect to clinical trials in the U.S. and our ability to resolve any issues to the satisfaction of the FDA or any regulatory agency in a timely •our ability to replicate the efficacy and safety demonstrated in theRAPIDe-1andCHAPTER-1Phase 2 study in ongoing and future •risks arising from epidemic diseases which may adversely impact our business, nonclinical studies and clinical trials, the outcome and timing of regulatory approvals and the value of our ordinary shares;•the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates IR and XR or any otherproduct candidate that we may develop in the future;•our ability to market, commercialize and achieve market acceptance for our product candidates IR and XR or any of our other productcandidates that we may develop in the future, if approved;•our ability to establish commercial capabilities or enter into agreements with third parties to market, sell and distribute our productcandidates; or all of which may never reach the regulatory approval stage;•our ability to raise capital when needed and on acceptable terms; •our ability to enter into any new licensing agreements or to maintain any licensing agreements with respect to our product candidates;•our reliance on collaboration partners and licensees, whose actions we cannot control; •the willingness of private insurers and other payors to provide reimbursement for our products;•regulatory developments in the United States, the European Union and other jurisdictions; S-iv •our ability to protect our intellectual property andknow-howand operate our busine